Pseudomyxoma peritonei

Bevan, K.; Mohamed, Faheez; Moran, Brendan

doi:10.4251/wjgo.v2.i1.44

Cited by 92 publications

(114 citation statements)

References 0 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…According to several phase I and II prospective trials, 5-year survivals have ranged between 66% and 97% (Stewart et al, 2005). It must be taken in mind that, because of the limited data on prognostic factors for this procedure in the setting of appendiceal primary tumors, further well designed, prospective, multi-institutional study are required (Bevan et al, 2010;Roviello et al, 2011).…”

Section: Advanced Oncological Surgery In Pseudomyxoma Peritoneimentioning

confidence: 99%

Abdominal Advanced Oncologic Surgery

Pasqual¹,

Bertozzi²

2012

Abdominal Surgery

View full text Add to dashboard Cite

Section: Advanced Oncological Surgery In Pseudomyxoma Peritoneimentioning

confidence: 99%

Abdominal Advanced Oncologic Surgery

Pasqual¹,

Bertozzi²

2012

Abdominal Surgery

View full text Add to dashboard Cite

“…Excess peritoneal mucin accumulation and intestinal blockage often lead to nutritional compromise with subsequent patient demise [1,2]. PMP mucin secreting tumour cells originate commonly from ruptured appendix tumours although they may also arise from colorectal, ovarian, pancreas, lungs and other sources [3,4]. Current treatment methods involving laparotomy, cytoreduction and hyperthermic intraperitoneal chemotherapy, as first instituted by Sugarbaker [5], has improved patient 5 year survival to > 80 % [6].…”

Section: Introductionmentioning

confidence: 99%

Assessment of a novel mucolytic solution for dissolving mucus in pseudomyxoma peritonei: an ex vivo and in vitro study

Pillai

Akhter

Morris

2017

Pleura and Peritoneum

View full text Add to dashboard Cite

Background: Pseudomyxoma peritonei (PMP) is difficult to treat. Intraperitoneal delivery of mucolytic solutions might potentially improve therapy, in addition to surgical cytoreduction and hyperthermic intraperitoneal chemotherapy. Methods: Comparison of mucolytic effect of two formulations (control: bromelain 300 µg/mL + N-Acetylcystein 250 mM; test: bromelain 200 µg/mL + 200 mM cysteamine) in vitro on a mucin producing cell lines (HT29) and ex vivo on mucus obtained from 18 PMP patients. Mucin plugs were classified according to their density into three categories: hard, semi hard and soft. Simulation of peritoneal washing ex vivo using a closed heated circulating pump. Results: Solubilisation was faster with the test vs. the control formulation (90 vs. 180 min) for dissolving the soft mucin plugs (p < 0.05). The test solution was also more effective in dissolving the hard mucus plugs compared to control (82.5 ± 2.74 % vs. 36.33 ± 3.27 %). All mucin types disintegrated in simulated peritoneal washing. Cytotoxicity of the test solution on HT29 cell line was time-dependent. Conclusions: The test formulation is more effective and faster than the control formulation in dissolving mucus plugs of various densities. Mucus plugs were all solubilised after 40 min in simulated peritoneal washing. This novel mucolytic formulation might pave the way for an effective and less invasive therapy of PMP in the future.

show abstract

“…For example, even 20 years ago patients with pseudomyxoma peritonei were suggested only interval debulking to improve their quality of life but without a chance for a long-term survival [1]. Suggesting radical peritonectomy aimed at removing as much macroscopic disease as possible followed by HIPEC to eliminate microscopic and residual disease resulted in significant improvement of outcomes with 5-and 10-years survival being 40−87 and 50% to 74% respectively [2][3][4][5][6][7][8][9][10]. However, combination cytoreductive surgery + HIPEC are considered as a treatment modality with high rate of postoperative morbidity and mortality by some authors [11].…”

Section: Introductionmentioning

confidence: 99%

Does Hyperthermic Intraperitoneal Perfusion Affect the Outcome After Cytoreductive Surgery?

Gs¹,

Gi²,

Ky³

et al. 2017

J Clin Gastroenterol Hepatol

View full text Add to dashboard Cite

Outcomes of hyperthermic intraperitoneal chemoperfusion (HIPEC) added to cytoreductive surgery were studied in experimental and clinical settings. 32 female Wistar rats with peritoneal carcinomatosis were used in the experiment. Rats were randomized into 4 groups (8 rats each): I -control group; II -cytoreduction; III -hyperthermic intraperitoneal perfusion without drugs (HIPEP); IV -cytoreduction + HIPEP.In clinical part of the study 7 patients with pseudomixoma peritonei underwent cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (HIPEC). As the result of the experiment post-operative morbidity taken as post-operative complications and the restoration of body weight after surgery was more severe in animals who received combination of cytoreductive surgery + HIPEP compared to animals who received the surgery or HIPEP alone.The median survival of rats in the control group, cytoreduction, HIPEP and cytoreduction + HIPEP were 8.5, 25 (p=0.007 compared to control), 23.5 (p=0.003 compared to control) and 19.5 (p=0.034 compared to control) days respectively. In clinical part of the study post-operative complications were registered in 2 patients, one of them died on day 12 after the surgery.The pattern of complications was mainly determined by the volume of cytoreductive surgery. Two more patients died due to the tumor progression. Four patients are currently alive with follow-up 4−28 months. Cytoreductive surgery combined with HIPEC should be performed in patients with pseudomyxoma peritonei to increase their survival time. Morbidity from this approach has to be reduced by formulating the strategy of optimal cytoreduction in the studies including larger number of patients.

show abstract

Pseudomyxoma peritonei

Cited by 92 publications

References 0 publications

Abdominal Advanced Oncologic Surgery

Abdominal Advanced Oncologic Surgery

Assessment of a novel mucolytic solution for dissolving mucus in pseudomyxoma peritonei: an ex vivo and in vitro study

Does Hyperthermic Intraperitoneal Perfusion Affect the Outcome After Cytoreductive Surgery?

Contact Info

Product

Resources

About